Carvedilol: Therapeutic application and practice guidelines

Pharmacotherapy

Volumn 18, Issue 4, 1998, Pages 729-737

  Bleske, Barry E ^a   Gilbert, Edward M ^b   Munger, Mark A ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CIMETIDINE; CLONIDINE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOXETINE; HYDRALAZINE; INSULIN; MIBEFRADIL; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PAROXETINE; QUINIDINE; RESERPINE; RIFAMPICIN; SERTRALINE; VASODILATOR AGENT; VERAPAMIL;

BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; EXERCISE TOLERANCE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPOTENSION; MORBIDITY; MORTALITY; PATIENT EDUCATION; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; HEART DISEASES; HUMANS; PRACTICE GUIDELINES; PROPANOLAMINES;

EID: 0031827190     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Katz AM. Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med 1990;322:100-10.
2. Massie BM, Shah NB. Future approaches to pharmacologic therapy for congestive heart failure. Curr Opin Cardiol 1995;10:229-37.
3. Metra M, Nardi M, Giubbini R, Dei-Cas L. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87.
4. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
5. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-18.
6. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506.
7. Colucci WS, Packer M, Bristow MR, for the U.S. Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
8. Packer M, Colucci WS, Sackner-Bernstein JD, for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Circulation 1996;94:2793-9.
9. Bristow MR, Gilbert EM, Abraham WT, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
10. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
11. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
13. Bristow MR, Hershberger RE, Port JD, et al. β-Adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990;82(suppl I):I-12-25.
14. Asano K, Dutcher DL, Port JD, et al. Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 1997;95:1193-2000.
15. Bristow MR, Ginsburg R, Minobe WA, et al. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human heart. N Engl J Med 1982;307:205-11.
16. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
17. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-33.
18. Bartsch W, Sponer G, Stren K, et al. Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol 1990;38(suppl 2):S104-7.
19. Ruffolo RR Jr, Gelai M, Heible JP, Willette RN. Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38(suppl 2):S23-32.
20. Bristow MR, Larrabee P, Muller-Beckmann B, et al. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Invest 1992;70:S105-13.
21. Das Gupta P, Broadhurst P, Lahiri A. The effects of intravenous carvedilol, a new multiple action vasodilating β-blocker, in congestive heart failure. J Cardiovasc Pharmacol 1991;18(suppl 4):S12-16.
22. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17(suppl 11):S81-4.
23. Bristow MR, Larrabee P, Minobe W, et al. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 1992;19(suppl 1):S68-80.
24. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing human heart. Circulation 1996;94:2817-25.
25. Samama P, Pei G, Costa T, Cotecchia S, Lefkowitz RJ. Negative antagonists promote an inactive conformation of the β-adrenergic receptor. Mol Pharmacol 1994;45:390-4.
26. 2-adrenergic receptor. Science 1994;264:582-6.
27. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M. Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 1994;45:490-9.
28. Lowes BD, Chidiac P, Olsen S, et al. Clinical relevance of inverse agonism and quanine nucleotide modulatable binding properties of β-adrenergic receptor blocking agents. Circulation 1994;90:1-543.
29. Strein K, Sponer G. Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule. Z-Kardiol 1990;79(suppl 3):89-98.
30. Yue T-L, Cheng H-Y, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-8.
31. Yue T-L, McKenna PJ, Lysko PG, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new antihypertensive prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 1992;97:209-16.
32. Yue-T-L, McKenna PJ, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new β-adrenergic antagonist and vasodilator antihypertensive drug, inhibits Superoxide release from human neutrophils. Eur J Pharmacol 1992;214:277-80.
33. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996;17(suppl B):24-9.
34. Ohlstein EH, Douglas SA, Sung C-P, et al Carvedilol, a cardiovascular drug, prevents smooth muscle proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993;90:6189-93.
35. von Mollendorff E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol 1987;33:511-13.
36. Neugebauer G, Akpan W, Kaufmann B, Reiff K. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol 1990;38:S108-11.
37. Varin F, Cubeddu LX, Powell JF. Liquid Chromatographic assay and disposition of carvedilol in healthy volunteers. J Pharmaceut Sci 1986;75:1195-7.
38. Fujimaki M, Halusui H, Haseqawa H. Assay and disposition of carvedilol enantiomers in humans and monkeys: evidence of Stereoselective pressystemic metabolism. J Pharmaceut Sci 1990;79:568-72.
39. SmithKline Beecham Pharmaceuticals, Clinical Research and Development. Investigator brochure: carvedilol. Philadelphia;1995.
40. Packer M, Bristow MR, Cohn JN, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
41. Cohn JN, Fowler MR, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure [abstr]. J Am Coll Cardiol 1996;27(suppl A):169A.
42. Gilbert EM, Colucci WS, Fowler MB, for th U.S. Carvedilol Heart Failure Study Group. Carvedilol without ACE inhibition in the treatment of patients with moderate to severe heart failure [abstr]. Circulation 1996;94(suppl I):I-663.
43. Grunden JW, Gilbert EM, Munger MA. Augmented digoxin concentrations with carvedilol in mild-moderate heart failure. Am J Ther 1994;1:157-61.
44. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997;79:794-8.
45. Sackner-Bernstein J, Krum H, et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term benefit? [abstr]. Circulation 1995;92(suppl I):I-395.